TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3569063

Group type: EXPERIMENTAL
Intervention: Ismo 20 (40 mg IS-5-N daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corangin 20 (40 mg IS-5-N daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corangin 40 (40 mg IS-5-N once a day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corangin 60 (60 mg IS-5-N once a day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained release preparations (Corangin 40 and Corangin 60)
Number of subjects: 12
Study: 30383673

Group type: EXPERIMENTAL
Intervention: Electromagnetic acupuncture
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 104
Study: 27749578

Group type: EXPERIMENTAL
Intervention: Group-based intervention
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Individual-based intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 150
Study: 24886681

Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF) for 5 days followed by autologous MSCs peripheral‐vein infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular liver‐supportive treatment only (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MSC therapy
Number of subjects: 40
Study: 22225697

Group type: EXPERIMENTAL
Intervention: GPM + DBT‐M treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: GPM alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 60
Study: 20041478

Group type: EXPERIMENTAL
Intervention: Psycho-education aimed at improving knowledge, attitudes, and adherence behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions targeting medication adherence as a secondary outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psycho-education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Person-centered approach considering risk factors for non-adherence
Number of subjects: 0
Study: 17921245

Group type: EXPERIMENTAL
Intervention: Mobile phone technology for symptom monitoring
Number of subjects: 6
Study: 16364056

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole orally for 2 days b.i.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12530623

Group type: EXPERIMENTAL
Intervention: vdelta75 (75% of the difference between vLT and vVO2 max)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: vdelta50 (50% of the difference between vLT and vVO2 max)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: vdelta100 (100% of the difference between vLT and vVO2 max)
Number of subjects: 9
Study: 10447055

Group type: EXPERIMENTAL
Intervention: Liquid cooling (L)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Air cooling (A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No cooling (N)
Number of subjects: 8
Study: 8605781

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol and 75 micrograms gestodene
Number of subjects: 479

Group type: COMPARATOR
Intervention: 20 micrograms ethinylestradiol and 150 micrograms desogestrel
Number of subjects: 479
Study: 2179218

Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 0
Study: 7384377

Group type: EXPERIMENTAL
Intervention: Experimental manipulation of signal value for 1 out of 10 stimuli presented 3 times in random order.
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Manipulation of the number of series presented to subjects (1, 2, and 3 series).
Number of subjects: 228

Group type: COMPARATOR
Intervention: Variations such as increased motivation, auditory vs. visual stimuli, and different scoring procedures.
Number of subjects: 228
Study: 31609896

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 178
Study: 31278767

Group type: EXPERIMENTAL
Intervention: Immediate loading (48 hours post-surgery)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Early loading (2 weeks after surgery)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (Immediate and Early loading)
Number of subjects: 24
Study: 28696373

Group type: EXPERIMENTAL
Intervention: Weekly upper limb rehabilitation for 24 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: No rehabilitation
Number of subjects: 31
Study: 25857612

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted dietary recording
Number of subjects: 110
Study: 23686619

Group type: EXPERIMENTAL
Intervention: Community-based child sexual abuse prevention program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 20
Study: 21724070

Group type: EXPERIMENTAL
Intervention: 8% hydrogen peroxide bleaching agent during orthodontic treatment (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8% hydrogen peroxide bleaching agent after orthodontic treatment (group B)
Number of subjects: 40
Study: 19183470

Group type: EXPERIMENTAL
Intervention: MM+CBT (dual doctor model)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MM+I-CBT (single doctor model)
Number of subjects: 140

Group type: COMPARATOR
Intervention: MM only (control group)
Number of subjects: 140
Study: 17438504

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS 4IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 40
Study: 16739368

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 180

Group type: COMPARATOR
Intervention: 20 mg omeprazole MUPS
Number of subjects: 180

Group type: COMPARATOR
Intervention: 40 mg esomeprazole
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: lansoprazole
Number of subjects: 180

Group type: COMPARATOR
Intervention: esomeprazole
Number of subjects: 180
Study: 12873241

Group type: EXPERIMENTAL
Intervention: 1-6 UK units of alcohol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0 UK units of alcohol
Number of subjects: 80
Study: 10561173

Group type: EXPERIMENTAL
Intervention: Para-aortic (PA) radiotherapy (30 Gy/15 fractions/3 weeks)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Dogleg (DL) radiotherapy (30 Gy/15 fractions/3 weeks)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Para-aortic (PA) radiotherapy
Number of subjects: 478

Group type: COMPARATOR
Intervention: Dogleg (DL) radiotherapy
Number of subjects: 478
Study: 8687090

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by thymosin alpha1 + low-dose IFNalpha
Number of subjects: 22

Group type: COMPARATOR
Intervention: Chemotherapy (ifosfamide)
Number of subjects: 22
Study: 1873513

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sodium Nitroprusside
Number of subjects: 74
Study: 7087416

Group type: EXPERIMENTAL
Intervention: Closed-set Nonsense-Syllable Test presented monaurally at 90 dB SPL with cafeteria background noise at +20 dB S/N ratio
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Closed-set Nonsense-Syllable Test
Number of subjects: 38
Study: 31253454

Group type: EXPERIMENTAL
Intervention: Asthma self-management responsibilities transferred from mother to child
Number of subjects: 15
Study: 27613020

Group type: EXPERIMENTAL
Intervention: Banking Time
Number of subjects: 113

Group type: COMPARATOR
Intervention: Business-as-Usual
Number of subjects: 113

Group type: COMPARATOR
Intervention: Time-Control Comparison (Child Time)
Number of subjects: 113
Study: 25715364

Group type: EXPERIMENTAL
Intervention: HIFU combined with chemotherapy (group B)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Chemotherapy alone (group A)
Number of subjects: 185
Study: 24398076

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity intervention
Number of subjects: 232
Study: 23025474

Group type: EXPERIMENTAL
Intervention: Experimental coding strategies (including temporal fine structure stimulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Personal TEMPO+ speech processors (control)
Number of subjects: 12
Study: 19041284

Group type: EXPERIMENTAL
Intervention: 5 mg of sustained-release isradipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 24
Study: 17157900

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (500 mg bid)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study: 15888797

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 24 weeks
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 36 weeks
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 48 weeks
Number of subjects: 287

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha‐2b and ribavirin for 36 weeks
Number of subjects: 287

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha‐2b and ribavirin for 48 weeks
Number of subjects: 287
Study: 11978146

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60mg with grapefruit juice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desloratadine 5mg with grapefruit juice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fexofenadine 60mg without grapefruit juice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Desloratadine 5mg without grapefruit juice
Number of subjects: 24
Study: 9797051

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) 0.12%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tetracycline HCl (TTC) 10 mg/ml
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) 50 mg/ml
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 15
Study: 7638969

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 60 mg once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1709020

Group type: EXPERIMENTAL
Intervention: Budesonide nasal aerosol 400 micrograms/day for 21 days and oxymetazoline nasal drops for the first three days
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Terfenadine tablet 60 mg twice/day
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/day with or without oxymetazoline nasal drops
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Budesonide with oxymetazoline for the first three days
Number of subjects: 130
Study: 508019

Group type: EXPERIMENTAL
Intervention: vasodilators
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: vasodilators plus diuretics
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sympatholytics
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sympatholytics plus diuretics
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sympatholytics, diuretics, and vasodilators
Number of subjects: 10
Study: 30318946

Group type: COMPARATOR
Intervention: Standard postoperative precautions with mandatory assistive devices and knee brace for 6 weeks
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Non-precaution group with assistive devices only if needed
Number of subjects: 394

Group type: COMPARATOR
Intervention: Knee brace prescribed in precaution group
Number of subjects: 394
Study: 28538371

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 65
Study: 25609501

Group type: EXPERIMENTAL
Intervention: High value elements (HVEs) of practice redesign
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 23684679

Group type: EXPERIMENTAL
Intervention: MDCT group (n=133)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group (n=133)
Number of subjects: 266
Study: 20545835

Group type: EXPERIMENTAL
Intervention: Auto-adjusting positive airway pressure (APAP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 12
Study: 19994687

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Jiaji (EX‐B 2) combined with blood‐letting and cupping
Number of subjects: 53

Group type: COMPARATOR
Intervention: Oral administration of Valaciclovir Hydrochlordide, Indomethacin, Vitamin B1 and Vitamin B12
Number of subjects: 53
Study: 16962390

Group type: EXPERIMENTAL
Intervention: Tropisetron preparation 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tropisetron preparation 2
Number of subjects: 20
Study: 15295952

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (ASF) mouthrinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) mouthrinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Antimicrobial host proteins (LLL) mouthrinse
Number of subjects: 12
Study: 11799859

Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 106

Group type: COMPARATOR
Intervention: Brandt & Daroff exercises
Number of subjects: 106
Study: 9478093

Group type: COMPARATOR
Intervention: Cholinesterase activity in blood serum of workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholinesterase activity in plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in cholinesterase activity
Number of subjects: 0
Study: 7894213

Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine GITS administered at 1000 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine GITS administered at 2200 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo period prior to nifedipine administration
Number of subjects: 10
Study: 2821953

Group type: EXPERIMENTAL
Intervention: Antidepressants and electroconvulsive therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serotonin uptake blockers (alaproclate and zimeldine hydrochloride)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nortriptyline hydrochloride and electroconvulsive therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Clinically recovered, drug-free patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Low pretreatment Bmax
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Binding parameters
Number of subjects: 51
Study: 31927533

Group type: EXPERIMENTAL
Intervention: 6-gene signature (PEX11A, NLRP2, SERPINE1, UPK, CTTN, D2HGDH)
Number of subjects: 0
Study: 29299790

Group type: EXPERIMENTAL
Intervention: mHealth app (mVIP) with self-care strategies
Number of subjects: 80
Study: 26677212

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.0 g/d)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 g/d)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 25625366

Group type: EXPERIMENTAL
Intervention: Optisol GS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Life4°C
Number of subjects: 27
Study: 23728101

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE, n=13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resistive exercise (RE, n=13)
Number of subjects: 26
Study: 21126528

Group type: EXPERIMENTAL
Intervention: Lesions in the medial prefrontal cortex (mPFC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesions in the right mPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesions in the left posterior cortex (PC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesions in the left hemisphere
Number of subjects: 0
Study: 18957452

Group type: EXPERIMENTAL
Intervention: Health care reform support
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Offering health coverage
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Plans to terminate coverage or restrict eligibility
Number of subjects: 1003
Study: 17203535

Group type: EXPERIMENTAL
Intervention: Colonic exclusion and end-to-side colorectal anastomosis (n = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Subtotal colectomy and end-to-end colorectal anastomosis (n = 18)
Number of subjects: 32
Study: 14615296

Group type: EXPERIMENTAL
Intervention: MRI-based anatomic analysis of the brains with semilobar holoprosencephaly
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Analysis of the rostro-caudally aligned midline gray matter 'seam'
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Assessment of telencephalic growth
Number of subjects: 7
Study: 12354713

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide with oxygen
Number of subjects: 124

Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 124
Study: 9535210

Group type: EXPERIMENTAL
Intervention: VIP (cisplatin/ifosfamide/etoposide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CAV (cyclophosphamide/doxorubicin/vincristine)
Number of subjects: 0
Study: 8136590

Group type: EXPERIMENTAL
Intervention: Percutaneous varicocele embolotherapy
Number of subjects: 59
Study: 2688231

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg daily for 22 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg daily for 14 days (after NAC or placebo treatment)
Number of subjects: 37
Study: 766252

Group type: EXPERIMENTAL
Intervention: Intrathoracic BCG (single dose)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 30980514

Group type: EXPERIMENTAL
Intervention: golimumab 2 mg/kg at weeks 0, 4, and every 8 weeks thereafter
Number of subjects: 480

Group type: COMPARATOR
Intervention: placebo-crossover group
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: golimumab 2 mg/kg
Number of subjects: 480
Study: 26788833

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Dexamethasone 0.1%/tobramycin 0.3% (DM/T)
Number of subjects: 627
Study: 26206652

Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy (GDT) using stroke volume variation
Number of subjects: 135
Study: 23480249

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 54
Study: 22080238

Group type: EXPERIMENTAL
Intervention: Etomidate (group T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol (group B)
Number of subjects: 0
Study: 19639067

Group type: EXPERIMENTAL
Intervention: Single-implant group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Two-implant group
Number of subjects: 86
Study: 17182196

Group type: EXPERIMENTAL
Intervention: Safer sex behavioral intervention (EDGE)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Time-equivalent diet-and-exercise attention-control condition
Number of subjects: 341
Study: 15489480

Group type: EXPERIMENTAL
Intervention: OBF pneumotonometer
Number of subjects: 127

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 127

Group type: COMPARATOR
Intervention: Tono-Pen
Number of subjects: 127
Study: 11878524

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2.5 mg with fentanyl 0.025 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg with fentanyl 0.025 mg
Number of subjects: 40
Study: 9187842

Group type: EXPERIMENTAL
Intervention: Petrolatum
Number of subjects: 20
Study: 8171069

Group type: EXPERIMENTAL
Intervention: PGE1 treatment group
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study: 3286673

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin delivery (5.2 mU kg‐1 min‐1, 2/11 min on/off)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous insulin delivery (0.8 mU kg‐1 min‐1 for normal men; 0.15 mU kg‐1 min‐1 for type 1 diabetic patients)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intermittent insulin delivery (0.97 mU kg‐1 min‐1 for 2 min, followed by 11 min no infusion for type 1 diabetic patients)
Number of subjects: 16
Study: 30211787

Group type: EXPERIMENTAL
Intervention: Open semi-extended parapatellar tibial nailing technique (SEK)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard infrapatellar tibial nailing technique (FK)
Number of subjects: 47
Study: 28538964

Group type: EXPERIMENTAL
Intervention: mHELP (modified Hospital Elder Life Program)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: mHELP
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control
Number of subjects: 377
Study: 25653317

Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 105

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 105
Study: 23642377

Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (monthly or as-needed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual Intraretinal Fluid (IRF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormally thin (<120 μm) or thick (>212 μm) retinas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger neovascular lesions or foveal scar
Number of subjects: 0
Study: 21863652

Group type: EXPERIMENTAL
Intervention: Freedom SOLO valve
Number of subjects: 69

Group type: COMPARATOR
Intervention: SJM mechanical valve
Number of subjects: 69
Study: 19309712

Group type: EXPERIMENTAL
Intervention: Primary PCI with triple antiplatelet therapy
Number of subjects: 995

Group type: COMPARATOR
Intervention: Intra-aortic balloon counterpulsation during primary PCI
Number of subjects: 995

Group type: COMPARATOR
Intervention: Reinfarction
Number of subjects: 995

Group type: COMPARATOR
Intervention: Stent thrombosis
Number of subjects: 995
Study: 16681559

Group type: EXPERIMENTAL
Intervention: Human insulin inhalation powder (HIIP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) insulin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both SC and HIIP
Number of subjects: 16
Study: 15579791

Group type: EXPERIMENTAL
Intervention: 1273AGA allele of the SUR1 gene
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: High-risk haplotype of the SUR1 gene
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: High-risk haplotype of the SUR1 gene and 23K allele of the Kir6.2 gene
Number of subjects: 490
Study: 11254753

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) providing 2.0 g/day of eicosapentaenoate (EPA) and 1.4 g/day of docosahexaenoate (DHA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 15